This Week in Cardiology

Social media tension, bempedoic acid, hopeful news from CMS, and carotid interventions are the topics discussed by Dr John Mandrola in this week's podcast.

More fuel piled onto the EXCEL trial controversy, GI bleeds in AF, medical education, and revascularization procedures are covered by Dr John Mandrola in this week's podcast.

Cardiac stents, cardio-oncology, VT ablation, acute AF are the topics discussed by Dr John Mandrola in this week's podcast.

The NEJM retraction, TAVR 5-year results, ICD selection, long QT reversals, and lung cancer screening are the topics discussed by John Mandrola, MD in this week's podcast.

Executive physicals, coconut fat, leadless pacemakers, coils, and independent nurse practitioners and physician assistants are the topics discussed by Dr. John Mandrola in this week's podcast.

EXCEL, amyloid cardiomyopathy, drug prices, palliative care in cardiology, and gender bias are the topics covered by Dr John Mandrola in this week's podcast.

The Excel trial, peripartum cardiomyopathy, marathoning, hot-spotting, and leadership in innovation are the topics discussed by Dr. John Mandrola in this week's podcast.

The EXCEL debate, the NOBLE trial, alcohol and AF, cardiac devices, and hospital consolidation are the topics covered by John Mandrola, MD, in this week's podcast.

A risk score for device infection, conflicts of interest, the Fragility Index, rhythm vs rate control for AF in HFpEF, and year-end highlights are discussed by John Mandrola, MD, in this week's podcast.

The EXCEL trial controversy, and Dr John Mandrola's experience with vernakalant at FDA are the topics covered in this week's podcast.

Vernakalent, CV death in cancer patients, dapagliflozin, and sacubitril/valsartan are the topics Dr. John Mandrola discusses in this week's podcast.

Highlights from the 2019 AHA meeting are analyzed by Dr John Mandrola in this week's podcast.

Interruption of oral anticoagulation, marijuana and stroke, ORBITA substudy, ISCHEMIA medical therapy targets, and more on AHA are the topics discussed by Dr. John Mandrola in this week's podcast.

Words that harm, statins, thyroid replacement, and the ISCHEMIA trial are the topics discussed by Dr John Mandrola in this week's podcast.

Mortality after AF ablation, cardiac rehab programs, hypertrophic cardiomyopathy, and clinician wellness are the topics Dr. John Mandrola discusses in this week's podcast.

AF after TAVR, opioids after cardiac devices, hypertension in black adults, and post-cardiac surgery AF are the topics Dr John Mandrola discusses in this week's podcast.

The Nobel Prize, more on the EXCEL trial, the costs of cardiac tests, familial hypercholesterolemia, and burnout are the topics discussed by Dr John Mandrola in this week's podcast.

Left main PCI vs CABG trials and TAVR vs SAVR—in this week's podcast, Dr John Mandrola takes a deeper dive.

Social effects of medicine, SGLT2 inhibitors, CIED infections, equity in cardiology, and post-PCI anti-thrombotic therapy are the topics discussed by Dr John Mandrola in this week's podcast.

The polypill, dapagliflozin, TAVR, and video games are discussed by John Mandrola, MD, in this week's podcast.

More from ESC: Antiplatelets and NOACs, blood glucose control, high sensitivity troponin tests, and ICD trials are all covered by John Mandrola, MD, in this week's podcast.

Six major trials from the ESC meeting in Paris are reviewed by John Mandrola, MD, in this week's podcast.

Digital health, a new LDL-c lowering drug, PCSK9i outcomes in higher risk patients, and an ESC preview are discussed by John Mandrola in this week's podcast.

TAVR, baroreflex activation for heart failure, dapagliflozin for HF, and myocardial viability are the topics discussed by John Mandrola in this week's podcast.

AI for AF detection, syncope and PE, thoracentesis, fish oil, and why doctors should organize are the topics covered by John Mandrola in this week's podcast.